The latest update is out from Roivant Sciences ( (ROIV) ).
On March 19, 2025, Roivant Sciences announced positive results from its subsidiary Immunovant’s studies on batoclimab for myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The Phase 3 MG study showed significant improvements in the MG-ADL score, while the Phase 2b CIDP study demonstrated promising initial results with a high responder rate. These findings support the potential of deeper IgG reduction in improving clinical outcomes for autoimmune diseases, although Immunovant plans to focus on advancing its lead asset IMVT-1402 for future studies rather than seeking immediate regulatory approval for batoclimab.
More about Roivant Sciences
Roivant Sciences Ltd. operates in the biopharmaceutical industry, focusing on developing innovative therapies for autoimmune diseases through its subsidiary, Immunovant, Inc. Immunovant is a clinical-stage immunology company that specializes in anti-FcRn technology, aiming to provide targeted treatments for complex autoimmune conditions.
YTD Price Performance: -11.34%
Average Trading Volume: 4,700,401
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.64B
Learn more about ROIV stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com